Shitaldas J Pamnani1, Staci L Sudenga2,3, Dana E Rollison2, Donna J Ingles4, Martha Abrahamsen2, Luisa L Villa5, Eduardo Lazcano-Ponce5,6, Yangxin Huang7, Amy Borenstein7, Anna R Giuliano2. 1. Graduate Medical Education, Brandon Regional Hospital, Tampa, Florida. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 3. Department of Epidemiology, Vanderbilt University Medical Center, Tennessee. 4. Vanderbilt Institute for Global Health, Nashville, Tennessee. 5. School of Medicine, University of São Paulo, Brazil. 6. Instituto Nacional de Salud Publica, Cuernavaca, Mexico. 7. Department of Epidemiology and Biostatistics, University of South Florida, Tampa.
Abstract
Background: The purpose of this study was to assess genital recurrence of human papillomavirus (HPV) genotypes included in the 9-valent vaccine and to investigate factors associated with recurrence among men in the HPV Infection in Men (HIM) Study. Methods: Men were followed every 6 months for a median of 3.7 years. HPV genotypes were detected using Roche linear array. Factors associated with type-specific HPV recurrence (infections occurring after a ≥12-month infection-free period) were assessed. Results: In type-specific analyses, 31% of prior prevalent and 20% of prior incident infections recurred. Among prevalent infections, HPV types 52, 45, 16, 58, and 6 and among incident infections, HPV types 58, 52, 18, 16, and 11 had the highest rates of recurrence. New sexual partners (male or female) and frequency of sexual intercourse with female partners were associated with HPV-6, -16, -31, and -58 infection recurrence. In grouped analyses, lifetime and new male sexual partners were associated with recurrence of prior incident infection with any of the 9 HPV types. Conclusions: Recurrence of genital HPV infections is relatively common among men and associated with high-risk sexual behavior. Further studies are needed to understand the role of HPV recurrence in the etiology of HPV-associated diseases.
Background: The purpose of this study was to assess genital recurrence of human papillomavirus (HPV) genotypes included in the 9-valent vaccine and to investigate factors associated with recurrence among men in the HPV Infection in Men (HIM) Study. Methods:Men were followed every 6 months for a median of 3.7 years. HPV genotypes were detected using Roche linear array. Factors associated with type-specific HPV recurrence (infections occurring after a ≥12-month infection-free period) were assessed. Results: In type-specific analyses, 31% of prior prevalent and 20% of prior incident infections recurred. Among prevalent infections, HPV types 52, 45, 16, 58, and 6 and among incident infections, HPV types 58, 52, 18, 16, and 11 had the highest rates of recurrence. New sexual partners (male or female) and frequency of sexual intercourse with female partners were associated with HPV-6, -16, -31, and -58 infection recurrence. In grouped analyses, lifetime and new male sexual partners were associated with recurrence of prior incident infection with any of the 9 HPV types. Conclusions: Recurrence of genital HPV infections is relatively common among men and associated with high-risk sexual behavior. Further studies are needed to understand the role of HPV recurrence in the etiology of HPV-associated diseases.
Authors: Regan N Theiler; Sherry L Farr; John M Karon; Pangaja Paramsothy; Raphael Viscidi; Ann Duerr; Susan Cu-Uvin; Jack Sobel; Keerti Shah; Robert S Klein; Denise J Jamieson Journal: Obstet Gynecol Date: 2010-06 Impact factor: 7.661
Authors: Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2014-07-26 Impact factor: 7.396
Authors: Howard D Strickler; Robert D Burk; Melissa Fazzari; Kathryn Anastos; Howard Minkoff; L Stewart Massad; Charles Hall; Melanie Bacon; Alexandra M Levine; D Heather Watts; Michael J Silverberg; Xiaonan Xue; Nicolas F Schlecht; Sandra Melnick; Joel M Palefsky Journal: J Natl Cancer Inst Date: 2005-04-20 Impact factor: 13.506
Authors: Shitaldas J Pamnani; Staci L Sudenga; Raphael Viscidi; Dana E Rollison; B Nelson Torres; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Jorge Salmeron; Manuel Quiterio; Yangxin Huang; Amy Borenstein; Anna R Giuliano Journal: Cancer Res Date: 2016-08-17 Impact factor: 12.701
Authors: Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt Journal: Cancer Res Date: 2012-09-27 Impact factor: 12.701
Authors: Anna R Giuliano; Eduardo Lazcano-Ponce; Luisa L Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary R Papenfuss; Martha Abrahamsen; Emily Jolles; Carrie M Nielson; Maria Luisa Baggio; Roberto Silva; Manuel Quiterio Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254
Authors: S Franceschi; X Castellsagué; L Dal Maso; J S Smith; M Plummer; C Ngelangel; S Chichareon; J Eluf-Neto; K V Shah; P J F Snijders; C J L M Meijer; F X Bosch; N Muñoz Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Jennifer S Smith; Danielle M Backes; Michael G Hudgens; Wenwen Mei; Hrishikesh Chakraborty; Eliane Rohner; Stephen Moses; Kawango Agot; Chris J L M Meijer; Robert C Bailey Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-05-10 Impact factor: 4.254